Scott D. Kelley
Keine laufenden Positionen mehr
Karriereverlauf von Scott D. Kelley
Ehemalige bekannte Positionen von Scott D. Kelley
| Unternehmen | Position | Beginn | Ende |
|---|---|---|---|
| FLEXION THERAPEUTICS, INC. | Technik-/Wissenschafts-/F&E-Leiter | 11.12.2017 | 31.05.2021 |
| Corporate Officer/Principal | 06.07.2016 | 11.12.2017 | |
| The University of California, San Francisco | Corporate Officer/Principal | 01.01.1990 | 01.01.2000 |
| Sanofi Corp. | Corporate Officer/Principal | - | - |
Aspect Medical Systems, Inc.
 Aspect Medical Systems, Inc. Medical SpecialtiesHealth Technology Aspect Medical Systems, Inc. developed and manufactured anesthesia monitoring system that was called Bispectral (BIS) system. The company was founded in 1987 and was headquartered in Norwood, MA. | Technik-/Wissenschafts-/F&E-Leiter | 01.07.2000 | - |
Ausbildung von Scott D. Kelley
| The University of California, San Francisco | Doctorate Degree |
| Stanford University | Graduate Degree |
Statistik
International
| Vereinigte Staaten | 6 |
Operativ
| Corporate Officer/Principal | 3 |
| Chief Tech/Sci/R&D Officer | 2 |
| Doctorate Degree | 1 |
Sektoral
| Health Technology | 3 |
| Consumer Services | 3 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
| Private Unternehmen | 3 |
|---|---|
Aspect Medical Systems, Inc.
Aspect Medical Systems, Inc. Medical SpecialtiesHealth Technology Aspect Medical Systems, Inc. developed and manufactured anesthesia monitoring system that was called Bispectral (BIS) system. The company was founded in 1987 and was headquartered in Norwood, MA. | Health Technology |
Flexion Therapeutics, Inc.
 Flexion Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Flexion Therapeutics, Inc. operates as a biopharmaceutical company, which engages in the development and commercialization of novel and local therapies. It specializes in the treatment of patients with musculoskeletal conditions including osteoarthritis. It offers products under the Zilretta brand, an extended-release corticosteroid approved to manage osteoarthritis knee pain. The company was founded by Michael D. Clayman and Neil Bodick on November 5, 2007 and is headquartered in Burlington, MA. | Health Technology |
| Sanofi Corp. |
- Börse
- Insiders
- Scott D. Kelley
- Erfahrung
